Please provide your email address to receive an email when new articles are posted on . Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. An ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results